Metabolic reprogramming is increasingly recognized as significantly linked to the pathogenesis and progression of major diseases. Exploring the intricacies of metabolic reprogramming in diseases holds the promise of unveiling novel therapeutic targets and biomarkers for advancing drug development and precision medicine. Nevertheless, this endeavor remains a challenge owing to the complexity and constantly evolving changes within the metabolic network. The Hu laboratory primarily focuses on exploring the impact of metabolic alterations on human diseases, with a particular focus on cancer and heart failure. This mission is fueled by pioneering innovative technologies, specifically mass spectrometry-based metabolomics and AI-driven multi-omics integration strategies. Our key objectives include: - Advancing mass spectrometry-based small-scale and single-cell metabolomics for ultra-sensitivity and high precision, coupled with AI-assisted multi-omics technologies including transcriptomics, proteomics, and metabolomics. - Gaining a comprehensive understanding of disease-specific metabolic reprogramming, as well as its functions and molecular regulatory mechanisms, specifically in tumors and cardiovascular diseases. - Identifying novel therapeutic targets and biomarkers for new drug development and precision medicine. In recent years, Dr. Hu has published several papers as (co)corresponding in journals including Cell Metabolism (2018), Nature Metabolism (2021a; 2021b), Nature Cancer (2022), Science Translational Medicine (2018), Journal of Clinical Investigation (2022), Nature Cardiovascular Research (2022), Nature Communications (2021a; 2021b; 2023), Cell Discovery (2022), Analytical Chemistry (2021), TrAC Trends in Analytical Chemistry (2023), Cancer Research (2024) etc. In total, Dr. Hu has published over 60 scientific papers, with more than 8000 citations (Google scholar). His findings have been highlighted in prestigious journals such as Science, Nature Cancer, Nature Reviews Cancer, and Science Translational Medicine etc. Dr. Hu serves as a reviewer for prestigious journals such as Nature Metabolism, Nature Communications, Science Advances, and Cell Reports etc., and editorial board member for Acta Pharmaceutica Sinica B, CTS-Clinical & Translational Sciences, and Life Metabolism etc.